Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis

Carin Waslo, Dennis Bourdette, Nora Gray, Kirsten Wright, Rebecca Spain

Research output: Contribution to journalReview article

Abstract

Abstract: Oxidative stress (OS), when oxidative forces outweigh endogenous and nutritional antioxidant defenses, contributes to the pathophysiology of multiple sclerosis (MS). Evidence of OS is found during acute relapses, in active inflammatory lesions, and in chronic, longstanding plaques. OS results in both ongoing inflammation and neurodegeneration. Antioxidant therapies are a rational strategy for people with MS with all phenotypes and disease durations. Purpose of review: To understand the function of OS in health and disease, to examine the contributions of OS to MS pathophysiology, and to review current evidence for the effects of selected antioxidant therapies in people with MS (PwMS) with a focus on lipoic acid (LA). Recent findings: Studies of antioxidant interventions in both animal and in vivo models result in reductions in serum markers of OS and increases in levels and activity of antioxidant enzymes. Antioxidant trials in PwMS, while generally underpowered, detect short-term improvements in markers of OS and antioxidant defenses, and to a lesser extent, in clinical symptoms (fatigue, depression). The best evidence to date is a 2-year trial of LA in secondary progressive MS which demonstrated a significant reduction of whole-brain atrophy and trend toward improvement in walking speed. Summary: Antioxidant therapy is a promising approach to treat MS across the spectrum and duration of disease. Rigorous and well-powered trials are needed to determine their therapeutic benefits.

Original languageEnglish (US)
Article number26
JournalCurrent Treatment Options in Neurology
Volume21
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Thioctic Acid
Multiple Sclerosis
Antioxidants
Oxidative Stress
Therapeutics
Chronic Progressive Multiple Sclerosis
Atrophy
Fatigue
Biomarkers
Inflammation
Phenotype
Recurrence
Health
Brain
Enzymes

Keywords

  • Antioxidant
  • Lipoic acid
  • Multiple sclerosis
  • Neurodegeneration
  • Neurological disease
  • Neurology

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis. / Waslo, Carin; Bourdette, Dennis; Gray, Nora; Wright, Kirsten; Spain, Rebecca.

In: Current Treatment Options in Neurology, Vol. 21, No. 6, 26, 01.06.2019.

Research output: Contribution to journalReview article

@article{53de3d837df146c3879a3c24632055e3,
title = "Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis",
abstract = "Abstract: Oxidative stress (OS), when oxidative forces outweigh endogenous and nutritional antioxidant defenses, contributes to the pathophysiology of multiple sclerosis (MS). Evidence of OS is found during acute relapses, in active inflammatory lesions, and in chronic, longstanding plaques. OS results in both ongoing inflammation and neurodegeneration. Antioxidant therapies are a rational strategy for people with MS with all phenotypes and disease durations. Purpose of review: To understand the function of OS in health and disease, to examine the contributions of OS to MS pathophysiology, and to review current evidence for the effects of selected antioxidant therapies in people with MS (PwMS) with a focus on lipoic acid (LA). Recent findings: Studies of antioxidant interventions in both animal and in vivo models result in reductions in serum markers of OS and increases in levels and activity of antioxidant enzymes. Antioxidant trials in PwMS, while generally underpowered, detect short-term improvements in markers of OS and antioxidant defenses, and to a lesser extent, in clinical symptoms (fatigue, depression). The best evidence to date is a 2-year trial of LA in secondary progressive MS which demonstrated a significant reduction of whole-brain atrophy and trend toward improvement in walking speed. Summary: Antioxidant therapy is a promising approach to treat MS across the spectrum and duration of disease. Rigorous and well-powered trials are needed to determine their therapeutic benefits.",
keywords = "Antioxidant, Lipoic acid, Multiple sclerosis, Neurodegeneration, Neurological disease, Neurology",
author = "Carin Waslo and Dennis Bourdette and Nora Gray and Kirsten Wright and Rebecca Spain",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s11940-019-0566-1",
language = "English (US)",
volume = "21",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis

AU - Waslo, Carin

AU - Bourdette, Dennis

AU - Gray, Nora

AU - Wright, Kirsten

AU - Spain, Rebecca

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Abstract: Oxidative stress (OS), when oxidative forces outweigh endogenous and nutritional antioxidant defenses, contributes to the pathophysiology of multiple sclerosis (MS). Evidence of OS is found during acute relapses, in active inflammatory lesions, and in chronic, longstanding plaques. OS results in both ongoing inflammation and neurodegeneration. Antioxidant therapies are a rational strategy for people with MS with all phenotypes and disease durations. Purpose of review: To understand the function of OS in health and disease, to examine the contributions of OS to MS pathophysiology, and to review current evidence for the effects of selected antioxidant therapies in people with MS (PwMS) with a focus on lipoic acid (LA). Recent findings: Studies of antioxidant interventions in both animal and in vivo models result in reductions in serum markers of OS and increases in levels and activity of antioxidant enzymes. Antioxidant trials in PwMS, while generally underpowered, detect short-term improvements in markers of OS and antioxidant defenses, and to a lesser extent, in clinical symptoms (fatigue, depression). The best evidence to date is a 2-year trial of LA in secondary progressive MS which demonstrated a significant reduction of whole-brain atrophy and trend toward improvement in walking speed. Summary: Antioxidant therapy is a promising approach to treat MS across the spectrum and duration of disease. Rigorous and well-powered trials are needed to determine their therapeutic benefits.

AB - Abstract: Oxidative stress (OS), when oxidative forces outweigh endogenous and nutritional antioxidant defenses, contributes to the pathophysiology of multiple sclerosis (MS). Evidence of OS is found during acute relapses, in active inflammatory lesions, and in chronic, longstanding plaques. OS results in both ongoing inflammation and neurodegeneration. Antioxidant therapies are a rational strategy for people with MS with all phenotypes and disease durations. Purpose of review: To understand the function of OS in health and disease, to examine the contributions of OS to MS pathophysiology, and to review current evidence for the effects of selected antioxidant therapies in people with MS (PwMS) with a focus on lipoic acid (LA). Recent findings: Studies of antioxidant interventions in both animal and in vivo models result in reductions in serum markers of OS and increases in levels and activity of antioxidant enzymes. Antioxidant trials in PwMS, while generally underpowered, detect short-term improvements in markers of OS and antioxidant defenses, and to a lesser extent, in clinical symptoms (fatigue, depression). The best evidence to date is a 2-year trial of LA in secondary progressive MS which demonstrated a significant reduction of whole-brain atrophy and trend toward improvement in walking speed. Summary: Antioxidant therapy is a promising approach to treat MS across the spectrum and duration of disease. Rigorous and well-powered trials are needed to determine their therapeutic benefits.

KW - Antioxidant

KW - Lipoic acid

KW - Multiple sclerosis

KW - Neurodegeneration

KW - Neurological disease

KW - Neurology

UR - http://www.scopus.com/inward/record.url?scp=85065405117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065405117&partnerID=8YFLogxK

U2 - 10.1007/s11940-019-0566-1

DO - 10.1007/s11940-019-0566-1

M3 - Review article

VL - 21

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 6

M1 - 26

ER -